Tulsa Wealth Advisors INC Makes New Investment in IQVIA Holdings Inc. $IQV

Tulsa Wealth Advisors INC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 5,824 shares of the medical research company’s stock, valued at approximately $1,313,000.

Several other hedge funds also recently made changes to their positions in the business. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA in the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new position in IQVIA during the 4th quarter worth $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the 4th quarter valued at $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $28,000. Finally, Activest Wealth Management lifted its position in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $168.14 on Friday. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s 50-day simple moving average is $173.63 and its 200 day simple moving average is $191.68. The firm has a market capitalization of $28.06 billion, a PE ratio of 20.84, a price-to-earnings-growth ratio of 1.44 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. The business’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research report on Friday, March 6th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Mizuho set a $215.00 target price on shares of IQVIA in a research report on Monday, February 23rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday. Finally, Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $222.56.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.